Evolution-based mathematical models significantly prolong response to abiraterone in metastatic castrate-resistant prostate cancer and identify strategies to further improve outcomes

Evolution-based mathematical models significantly prolong response to abiraterone in metastatic castrate-resistant prostate cancer and identify strategies to further improve outcomes

Background: Abiraterone acetate is an effective treatment for metastatic castrate-resistant prostate cancer (mCRPC), but evolution of resistance inevitably leads to progression. We present a pilot study in which abiraterone dosing is guided by evolution-informed mathematical models to delay onset of...

Full description

Bibliographic Details
Main Authors: Jingsong Zhang, Jessica Cunningham, Joel Brown, Robert Gatenby
Format: Article
Language:English
Published: eLife Sciences Publications Ltd 2022-06-01
Series:eLife
Subjects:
cancer evolution
metastatic prostate cancer
mathematical models
adaptive therapy
Online Access:https://elifesciences.org/articles/76284

Internet

https://elifesciences.org/articles/76284

Similar Items